Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.

Article  PubMed  Google Scholar 

Milà-Alomà M, Suárez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther Adv Neurol Disord. 2019;18(12):1756286419888819.

Article  Google Scholar 

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA. 2015;313(19):1924–38.

Article  PubMed  PubMed Central  Google Scholar 

Arenaza-Urquijo EM, Salvadó G, Operto G, Minguillón C, Sánchez-Benavides G, Crous-Bou M, et al. Association of years to parent’s sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. Neurology. 2020;95(15):e2065–74.

Article  PubMed  PubMed Central  Google Scholar 

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, et al. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease. JAMA Neurol. 2018;75(5):608–19.

Article  PubMed  PubMed Central  Google Scholar 

Bischof GN, Jacobs HIL. Subthreshold amyloid and its biological and clinical meaning: Long way ahead. Neurology. 2019;93(2):72–9.

Article  PubMed  Google Scholar 

Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, et al. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2014;83(5):434–40.

Article  PubMed  PubMed Central  Google Scholar 

Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, et al. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease. Mol Psychiatry. 2022;27(11):4781–9.

Article  PubMed  PubMed Central  Google Scholar 

Pelkmans W, Shekari M, Brugulat-Serrat A, Sánchez-Benavides G, Minguillón C, Fauria K, et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer’s disease progression. Alzheimers Dement. 2023.

Van Hulle C, Jonaitis EM, Betthauser TJ, Batrla R, Wild N, Kollmorgen G, et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimer’s disease clinical and pathological continuum. Alzheimers Dement. 2021;17(3):431–45.

Article  PubMed  Google Scholar 

Revised Criteria for Diagnosis and Staging of Alzheimer’s | AAIC [Internet]. Revised Criteria for Diagnosis and Staging of Alzheimer’s | AAIC. [cited 2024 Mar 20]. Available from: https://aaic.alz.org/diagnostic-criteria.asp.

Johnson SC, Suárez-Calvet M, Suridjan I, Minguillón C, Gispert JD, Jonaitis E, et al. Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. Alzheimers Res Ther. 2023;15(1):25.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR. PART and SNAP. Acta Neuropathol. 2014;128(6):773–6.

Article  PubMed  PubMed Central  Google Scholar 

Molinuevo JL, Gramunt N, Gispert JD, Fauria K, Esteller M, Minguillon C, et al. The ALFA project: A research platform to identify early pathophysiological features of Alzheimer’s disease. Alzheimers Dement (N Y). 2016;2(2):82–92.

Article  PubMed  Google Scholar 

Milà-Alomà M, Salvadó G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer’s continuum. Alzheimers Dement. 2020;16(10):1358–71.

Article  PubMed  Google Scholar 

Suárez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodríguez J, Milà-Alomà M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med. 2020;12(12):e12921.

Article  PubMed  PubMed Central  Google Scholar 

Milà-Alomà M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, et al. CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study. Neurology. 2021;97(21):e2065–78.

Article  PubMed  PubMed Central  Google Scholar 

Milà-Alomà M, Salvadó G, Shekari M, Grau-Rivera O, Sala-Vila A, Sánchez-Benavides G, et al. Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. J Prev Alzheimers Dis. 2021;8(1):68–77.

PubMed  Google Scholar 

Salvadó G, Shekari M, Falcon C, Operto G, Milà-Alomà M, Sánchez-Benavides G, et al. Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers. Brain Communications. 2022;4(3):fcac134.

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s & Dementia. 2015;11(1):1-15.e4.

Article  Google Scholar 

Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27.

Article  PubMed  PubMed Central  Google Scholar 

Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95–113.

Article  PubMed  Google Scholar 

Reitan R, Reitan R. Trail Making Test: Manual for Administration and Scoring. In 1992 [cited 2023 Oct 16]. Available from: https://www.semanticscholar.org/paper/Trail-Making-Test%3A-Manual-for-Administration-and-Reitan-Reitan/fb3612f133568883caa7c9c61e12d8cfe27807d3.

Gramunt N, Buschke H, Sánchez-Benavides G, Lipton RB, Peña-Casanova J, Diéguez-Vide F, et al. Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer’s and Family). J Alzheimers Dis. 2015;48(3):613–25.

Article  PubMed  Google Scholar 

Buschke H, Mowrey WB, Ramratan WS, Zimmerman ME, Loewenstein DA, Katz MJ, et al. Memory Binding Test Distinguishes Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. Arch Clin Neuropsychol. 2017;32(1):29–39.

Article  PubMed  PubMed Central  Google Scholar 

Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349–56.

Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, et al. Increased fibrillar amyloid- burden in normal individuals with a family history of late-onset Alzheimer’s. Proc Natl Acad Sci U S A. 2010;107(13):5949–54.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–47.

Article  PubMed  PubMed Central  Google Scholar 

Kärkkäinen M, Prakash M, Zare M, Tohka J, For The Alzheimer’s Disease Neuroimaging Initiative null. Structural Brain Imaging Phenotypes of Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD) Found by Hierarchical Clustering. Int J Alzheimers Dis. 2020;2020:2142854.

Hernández-Lorenzo L, Gil-Moreno MJ, Ortega-Madueño I, Cárdenas MC, Diez-Cirarda M, Delgado-Álvarez A, et al. A data-driven approach to complement the A/T/(N) classification system using CSF biomarkers. CNS Neurosci Ther. 2023.

Dong A, Toledo JB, Honnorat N, Doshi J, Varol E, Sotiras A, et al. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: links to cognition, progression and biomarkers. Brain. 2017;140(3):735–47.

PubMed  Google Scholar 

Gamberger D, Lavrač N, Srivatsa S, Tanzi RE, Doraiswamy PM. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer’s disease. Sci Rep. 2017;7(1):6763.

Article  PubMed  PubMed Central  Google Scholar 

Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;3(3):CD010803.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s Disease. Lancet Neurol. 2015;14(4):388–405.

Article  PubMed  PubMed Central  Google Scholar 

Ewers M, Biechele G, Suárez-Calvet M, Sacher C, Blume T, Morenas-Rodriguez E, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Mol Med. 2020;12(9): e12308.

Article  PubMed  PubMed Central  Google Scholar 

Dicks E, Vermunt L, van der Flier WM, Visser PJ, Barkhof F, Scheltens P, et al. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer’s disease. Neuroimage Clin. 2019;22: 101786.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Update on hypothetical model of Alzheimer’s disease biomarkers. Lancet Neurol. 2013;12(2):207–16.

Article  PubMed  PubMed Central  Google Scholar 

Convit A, de Asis J, de Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer’s disease. Neurobiol Aging. 2000;21(1):19–26.

Article  PubMed